Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Cincinnati
Patients were to receive sympathetic cardiac innervation testing with I-123 MIBG at baseline and again after receiving a titrate dose of beta-blocker. Data were to be assesses by repeated measures testing.
Age
20–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Essential hypertension with blood pressure less than 140/90 on either an ACE inhibitor or angiotensin receptor blocker
You may not be if
Known valvular heart disease of more than mild severity
Known coronary artery disease defined by an angiographic coronary artery stenosis greater than or equal to 50% luminal diameter narrowing, acute or previous myocardial infarction, or previous coronary revascularization
Known non-ischemic cardiomyopathy with left ventricular ejection fraction less than 50%
Atrial fibrillation
Current treatment with a β-adrenergic blocking drug or a calcium channel blocker
Current treatment with a psychoactive or other drug known to alter 123I-MIBG uptake
Participation in another research study within the prior 30 days
A life-limiting disease process that is likely to preclude completion of study participation
Pregnancy or breast feeding
Inability or unwillingness to provide informed consent
Baseline resting heart rate less than 65 beats per minute
Diabetes
Iodine allergy
Unwilling to sign informed consent.
Clareo Health | Sympathetic Nervous System Modulation in Hypertension
